Literature DB >> 19471675

Varicella: efficacy of two-dose vaccination in childhood.

Peter Wutzler1, Markus Knuf, Johannes Liese.   

Abstract

INTRODUCTION: Experience with one-dose varicella vaccination of children in the USA has shown that with high immunization coverage a marked decline in morbidity and mortality occurs. However, about one quarter of the vaccinees may develop breakthrough varicella. Although breakthrough infections are usually mild, the patients are potentially contagious.
METHODS: Selective literature search, review of congress papers, and evaluation of the consensus statement of an expert panel on the use of monovalent varicella vaccines.
RESULTS: Recent studies on the causes, effects, and consequences of breakthrough varicella after one-dose vaccination show that varicella vaccine should be given in two doses at least four to six weeks apart to achieve effective, long-lasting protection against chickenpox. Breakthrough disease cannot always be prevented, but two-dose vaccination offers significantly better protection than a single dose. These findings were considered in the approval process for the measles-mumps-rubella-varicella combination vaccines, which are licensed only for use in a two-dose schedule. DISCUSSION: The authors recommend the general implementation of a two-dose schedule for single-antigen varicella vaccines, which will continue to be available.

Entities:  

Keywords:  immunization coverage; prevention; prophylactic vaccination; vaccination recommendation; varicella

Year:  2008        PMID: 19471675      PMCID: PMC2680555          DOI: 10.3238/arztebl.2008.0567

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  19 in total

Review 1.  Control of varicella: why is a two-dose schedule necessary?

Authors:  Ann Arvin; Anne Gershon
Journal:  Pediatr Infect Dis J       Date:  2006-06       Impact factor: 2.129

2.  Second varicella vaccine dose.

Authors:  Barbara Kuter; Florian Schodel
Journal:  Pediatr Infect Dis J       Date:  2007-02       Impact factor: 2.129

3.  Metaanalysis of vaccine effectiveness in varicella outbreaks.

Authors:  Otmar Bayer; Ulrich Heininger; Cora Heiligensetzer; Rüdiger von Kries
Journal:  Vaccine       Date:  2007-07-27       Impact factor: 3.641

4.  Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection.

Authors:  Shu Li; Ivan S F Chan; Holly Matthews; Joseph F Heyse; Christina Y Chan; Barbara J Kuter; Karen M Kaplan; S J Rupert Vessey; Jerald C Sadoff
Journal:  Pediatr Infect Dis J       Date:  2002-04       Impact factor: 2.129

5.  The cost-effectiveness of routine childhood varicella vaccination in Germany.

Authors:  K Banz; S Wagenpfeil; A Neiss; A Goertz; U Staginnus; J Vollmar; P Wutzler
Journal:  Vaccine       Date:  2003-03-07       Impact factor: 3.641

6.  Primary vaccine failure after 1 dose of varicella vaccine in healthy children.

Authors:  David E Michalik; Sharon P Steinberg; Philip S Larussa; Kathryn M Edwards; Peter F Wright; Ann M Arvin; Haley A Gans; Anne A Gershon
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

7.  Loss of vaccine-induced immunity to varicella over time.

Authors:  Sandra S Chaves; Paul Gargiullo; John X Zhang; Rachel Civen; Dalya Guris; Laurene Mascola; Jane F Seward
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

8.  Younger age at vaccination may increase risk of varicella vaccine failure.

Authors:  Karin Galil; Elizabeth Fair; Norine Mountcastle; Phyllis Britz; Jane Seward
Journal:  J Infect Dis       Date:  2002-06-05       Impact factor: 5.226

9.  The burden of varicella complications before the introduction of routine varicella vaccination in Germany.

Authors:  Johannes G Liese; Veit Grote; Eva Rosenfeld; Richela Fischer; Bernd H Belohradsky; Rüdiger v Kries
Journal:  Pediatr Infect Dis J       Date:  2008-02       Impact factor: 2.129

10.  Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Mona Marin; Dalya Güris; Sandra S Chaves; Scott Schmid; Jane F Seward
Journal:  MMWR Recomm Rep       Date:  2007-06-22
View more
  5 in total

1.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

Review 2.  Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses.

Authors:  Paolo Bonanni; Anne Gershon; Michael Gershon; Andrea Kulcsár; Vassiliki Papaevangelou; Bernard Rentier; Catherine Sadzot-Delvaux; Vytautas Usonis; Timo Vesikari; Catherine Weil-Olivier; Peter de Winter; Peter Wutzler
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

Review 3.  Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections.

Authors:  A Sauerbrei
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-12       Impact factor: 3.267

4.  Heterogeneity in coverage for measles and varicella vaccination in toddlers - analysis of factors influencing parental acceptance.

Authors:  Christine Hagemann; Andrea Streng; Alexander Kraemer; Johannes G Liese
Journal:  BMC Public Health       Date:  2017-09-19       Impact factor: 3.295

5.  Epidemiology of Breakthrough Varicella after the Implementation of a Universal Varicella Vaccination Program in Taiwan, 2004-2014.

Authors:  Hao-Yuan Cheng; Luan-Yin Chang; Chun-Yi Lu; Li-Min Huang
Journal:  Sci Rep       Date:  2018-11-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.